These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18627571)

  • 1. Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours?
    Perret R; Ronchese F
    Tissue Antigens; 2008 Sep; 72(3):187-94. PubMed ID: 18627571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
    Rolle CE; Carrio R; Malek TR
    Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth.
    Kim EY; Teh SJ; Yang J; Chow MT; Teh HS
    J Immunol; 2009 Nov; 183(10):6051-7. PubMed ID: 19841176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
    Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
    J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
    Mueller K; Schweier O; Pircher H
    Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effector CD8+ T cells activated in vitro confer immediate and long-term tumor protection in vivo.
    Perret R; Ronchese F
    Eur J Immunol; 2008 Oct; 38(10):2886-95. PubMed ID: 18825745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of central memory CD8 T cells is independent of CD62L-mediated trafficking to lymph nodes.
    Wirth TC; Badovinac VP; Zhao L; Dailey MO; Harty JT
    J Immunol; 2009 May; 182(10):6195-206. PubMed ID: 19414773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
    Franceschetti M; Pievani A; Borleri G; Vago L; Fleischhauer K; Golay J; Introna M
    Exp Hematol; 2009 May; 37(5):616-628.e2. PubMed ID: 19375652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LiveCount Assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8(+) T-cells by flow cytometry.
    Devêvre E; Romero P; Mahnke YD
    J Immunol Methods; 2006 Apr; 311(1-2):31-46. PubMed ID: 16527300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer.
    Ramanathan S; Gagnon J; Ilangumaran S
    Arch Immunol Ther Exp (Warsz); 2008; 56(5):311-23. PubMed ID: 18836862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
    Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
    J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-21 and IL-15 cytokine DNA augments HSV specific effector and memory CD8+ T cell response.
    Rodrigues L; Nandakumar S; Bonorino C; Rouse BT; Kumaraguru U
    Mol Immunol; 2009 Apr; 46(7):1494-504. PubMed ID: 19233474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity towards intracellular pathogens.
    Huster KM; Stemberger C; Busch DH
    Curr Opin Immunol; 2006 Aug; 18(4):458-64. PubMed ID: 16765577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2-dependent pathways are essential for CD8+ T cell-mediated airway hyperresponsiveness and inflammation.
    Ohnishi H; Takeda K; Domenico J; Lucas JJ; Miyahara N; Swasey CH; Dakhama A; Gelfand EW
    J Allergy Clin Immunol; 2009 Jan; 123(1):249-57. PubMed ID: 19130938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different T cell receptor signals determine CD8+ memory versus effector development.
    Teixeiro E; Daniels MA; Hamilton SE; Schrum AG; Bragado R; Jameson SC; Palmer E
    Science; 2009 Jan; 323(5913):502-5. PubMed ID: 19164748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathways of memory CD8+ T-cell development.
    Bannard O; Kraman M; Fearon D
    Eur J Immunol; 2009 Aug; 39(8):2083-7. PubMed ID: 19637204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell-like plasticity of naïve and distinct memory CD8+ T cell subsets.
    Stemberger C; Neuenhahn M; Gebhardt FE; Schiemann M; Buchholz VR; Busch DH
    Semin Immunol; 2009 Apr; 21(2):62-8. PubMed ID: 19269852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Origin of CD8+ effector and memory T cell subsets.
    Stemberger C; Neuenhahn M; Buchholz VR; Busch DH
    Cell Mol Immunol; 2007 Dec; 4(6):399-405. PubMed ID: 18163951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase.
    Touvrey C; Derré L; Devevre E; Corthesy P; Romero P; Rufer N; Speiser DE
    J Immunol; 2009 Jun; 182(11):6718-26. PubMed ID: 19454666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth?
    Olver S; Apte S; Baz A; Kienzle N
    Tissue Antigens; 2007 Apr; 69(4):293-8. PubMed ID: 17389011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.